American Headache Society Annual Meeting

AUSTIN, Texas — More than 80% of those dealing with migraine or severe headaches reported cognitive impairment, with the most common being concentration difficulty, according to a presenter at the American Headache Society annual meeting.

AUSTIN, Texas – Children and adolescents diagnosed with anxiety, depression or both had greater headache-related disability compared with those without, according to a poster presented at the American Headache Society annual meeting.

AUSTIN, Texas — Migraine significantly affects work life and career in Canadian residents, with greater effect among those with more headache days per month, according to a poster at the American Headache Society annual meeting.

AUSTIN, Texas — One in five individuals with migraine used opioids or kept them on hand for treatment, with 83% reporting at least 1 day of opioid use in the past 30 days, according to Richard B. Lipton, MD, in this Healio video.

AUSTIN, Texas — Treatment with IV ketamine for pediatric refractory headache resulted in a 50% reduction in pain at discharge, with nearly two-thirds of patients not requiring rescue care within 1 month, according to a poster presentation.

AUSTIN, Texas — Treatment with candesartan led to significant reduction in mean monthly headache days and headache intensity in adolescents with high baseline migraine frequency, according to a poster presented here.

AUSTIN, Texas — Treatment with 10 mg zavegepant nasal spray resulted in better quality of life as early as 12 weeks and through 1 year in adult patients with migraine, according to research presented here.

Last week, Healio provided live coverage of the American Headache Society Annual Meeting in Austin, Texas, where health care professionals gathered for the latest updates on headache disorders.

AUSTIN, Texas — Long-term use of eptinezumab resulted in improvements in symptoms and headache days in patients with chronic migraine and medication-overuse headache, according to a poster presented here.

AUSTIN, Texas — Sustained freedom from pain and the most bothersome migraine symptom was achieved in more patients treated with investigational STS 101 compared with placebo, according to a study presented here.